The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma (Q44310180)

1 December 2017

The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma (English)

1 reference

1 December 2017

1 reference

Konstas AG

1

1 reference

1 December 2017

Kozobolis VP

2

1 reference

1 December 2017

Tersis I

3

1 reference

1 December 2017

Leech J

4

1 reference

1 December 2017

Stewart WC

5

1 reference

1 December 2017

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

17

1 reference

1 December 2017

1

1 reference

1 December 2017

41-46

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.eye.6700257

1 December 2017

0 references

cites work

Exfoliation syndrome and exfoliation glaucoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Prevalence, diagnostic features, and response to trabeculectomy in exfoliation glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Latanoprost 0.005% and anterior segment uveitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700257

7 January 2021

Identifiers

DOI

10.1038/SJ.EYE.6700257

1 reference

1 December 2017

1 reference